Silent Presentation, Significant Threat: Cold Agglutinin Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation
eJHaem · 2026-04 · 7 (2)
DOI: 10.1002/jha2.70266 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 20.03.2026. Verfasst von Zhuoyu An und 18 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Background
Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) is a curative therapeutic modality for hematological disorders, yet cold agglutinin syndrome (CAS) following haplo‐HSCT is exceedingly rare in the literature, leading to great diagnostic and therapeutic challenges in clinical practice. This study aimed to characterize the clinical manifestations, laboratory features, treatment strategies, and outcomes of post‐haplo‐HSCT CAS, and to provide clinical evidence for its early diagnosis and management.
Methods
We analyzed the data of all four patients with post‐haplo‐HSCT CAS at Peking University People's Hospital (2019–2024). Clinical data, including demographics, baseline characteristics, clinical manifestations, laboratory findings, therapeutic interventions, and follow‐up outcomes, were systematically collected and analyzed from electronic medical records.
Results
All four patients with CAS following haplo‐HSCT were male. CAS occurred at a median of 3.65 months post‐haplo‐HSCT (range: 1.9–9.7 months). All patients presented with severe hemolytic anemia (median Hb: 49.5 g/L, range: 22–59 g/L) and typical hemolytic laboratory findings, with no cold‐induced symptoms (acrocyanosis/Raynaud's phenomenon) observed. Three patients had concurrent infections, and two had underlying disease relapse/progression. Rituximab‐based regimens combined with supportive care achieved treatment response in three patients, with one patient showing no response. Two patients died from severe infections, and no CAS relapse was observed in all the survivors.
Conclusions
Post‐haplo‐HSCT CAS presents atypically without cold symptoms, is often triggered by infections or disease relapse amid immune dysregulation, and responds to rituximab‐based therapies. Clinicians should suspect CAS in haplo‐HSCT recipients with unexplained hemolytic anemia for prompt intervention. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
An, Z., Zhang, L., Zhao, P., He, Y., Fu, H., Zhang, Y., Mo, X., Wang, F., Yan, C., Sun, Y., Lv, M., Han, W., Chen, Y., Chang, Y., Wang, Y., Xu, L., Zhao, X., Huang, X., & Zhang, X. (2026). Silent Presentation, Significant Threat: Cold Agglutinin Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation. eJHaem, 7(2). https://doi.org/10.1002/jha2.70266
Vancouver
An Z, Zhang L, Zhao P, He Y, Fu H, Zhang Y, et al. Silent Presentation, Significant Threat: Cold Agglutinin Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation. eJHaem. 2026;7(2). doi:10.1002/jha2.70266
BibTeX
@article{An2026,
author = {An, Zhuoyu and Zhang, Liqian and Zhao, Peng and He, Yun and Fu, Haixia and Zhang, Yuanyuan and Mo, Xiaodong and Wang, Fengrong and Yan, Chenhua and Sun, Yuqian and Lv, Meng and Han, Wei and Chen, Yuhong and Chang, Yingjun and Wang, Yu and Xu, Lanping and Zhao, Xiangyu and Huang, Xiaojun and Zhang, Xiaohui},
title = {Silent Presentation, Significant Threat: Cold Agglutinin Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {2},
doi = {10.1002/jha2.70266}
}
EUVIMED